Избыточное потребление лекарственных средств для купирования головной боли при мигрени: результаты интернет-опроса
Избыточное потребление лекарственных средств для купирования головной боли при мигрени: результаты интернет-опроса
Ковальчук Н.А., Шагбазян А.Э., Табеева Г.Р. Избыточное потребление лекарственных средств для купирования головной боли при мигрени: результаты интернет-опроса. Consilium Medicum. 2021;23(11):847–851. DOI: 10.26442/20751753.2021.11.201146
________________________________________________
Koval'chuk NA, Shagbazian AE, Tabeeva GR. Abuse of medications for the treatment of migraines: results of an online survey. Consilium Medicum. 2021;23(11):847–851.
DOI: 10.26442/20751753.2021.11.201146
Избыточное потребление лекарственных средств для купирования головной боли при мигрени: результаты интернет-опроса
Ковальчук Н.А., Шагбазян А.Э., Табеева Г.Р. Избыточное потребление лекарственных средств для купирования головной боли при мигрени: результаты интернет-опроса. Consilium Medicum. 2021;23(11):847–851. DOI: 10.26442/20751753.2021.11.201146
________________________________________________
Koval'chuk NA, Shagbazian AE, Tabeeva GR. Abuse of medications for the treatment of migraines: results of an online survey. Consilium Medicum. 2021;23(11):847–851.
DOI: 10.26442/20751753.2021.11.201146
Обоснование. Чрезмерное использование средств для купирования головной боли является важным фактором формирования лекарственно-индуцированной головной боли. Цель. Выявить распространенность и паттерны использования лекарственных препаратов среди пациентов с мигренью и хроническим течением цефалгического синдрома. Материалы и методы. Проведен интернет-опрос среди 1598 пользователей сети Интернет, а также посредством социальных сетей (Instagram, Facebook, VK) с использованием Google Forms. Результаты. У 60% респондентов с хронической головной болью и симптомами мигрени не установлен достоверный диагноз. Более 70% пациентов выбирают препарат для купирования болевого синдрома самостоятельно и в 62,7% принимают препарат в каждый приступ головной боли. Заключение. Среди пациентов с хроническими головными болями при мигрени отмечается высокий процент лиц, злоупотребляющих симптоматическими средствами, что говорит о высоком риске формирования лекарственно-индуцированной головной боли.
Background. The abuse of headache medications is an important factor in the formation of drug-induced headache. Aim. To determine the prevalence and nature of drug use among patients with migraine and chronic cephalgic syndrome. Materials and methods. An Internet survey was conducted among 1598 Internet users, as well as through social networks (Instagram, Facebook, VK) using Google Forms. Results. 60% of respondents with chronic headache and migraine symptoms did not have a reliable diagnosis. More than 70% of patients choose a drug for pain relief on their own and 62.7% take the drug in every headache attack. Conclusion. Among patients with chronic headaches and migraines, there is a high percentage of people abusing symptomatic drugs, which indicates a high risk of drug-induced headache formation.
Keywords: chronic headache, excessive drug consumption, medication-overuse headache, migraine, self-medication
1. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12:575-83. DOI:10.1038/nrneurol.2016.124
2. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9:391-401.
DOI:10.1016/S1474-4422(10)70008-9
3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia. 2018;38:1-211.
4. Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-25. DOI:10.1177/0333102413512033
5. Aaseth K, Grande RB, Kvaerner KJ, et al. Prevalence of secondary chronic headaches in a population-based sample of 30–44-year-old persons. The Akershus study of chronic headache. Cephalalgia. 2008;28:705-13. DOI:10.1111/j.1468-2982.2008.01577.x
6. Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32(5):373-81. DOI:10.1177/0333102412438977, PMID: 22395797
7. Find NL, Terlizzi R, Munksgaard SB, et al. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain. 2015;17:20. DOI:10.1186/s10194-016-0612-2, PMID: 26957090, PMCID: PMC4783306
8. Bendtsen L, Munksgaard S, Tassorelli C, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34(6):426-33. DOI:10.1177/0333102413515338, PMID: 24322480
9. Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021;61(2):351-62. DOI:10.1111/head.14056, PMID: 33432635
10. Schwedt TJ, Buse DC, Argoff CE, et al. Medication Overuse and Headache Burden Results From the CaMEO Study. Neurol Clin Pract. 2021;11(3):216-26. DOI:10.1212/CPJ.0000000000001037
11. Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25(1):12-5.
DOI:10.1111/j.1468-2982.2004.00789.x, PMID: 15606564
12. Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18(9):891-902.
DOI:10.1016/S1474-4422(19)30146-2, PMID: 31174999
13. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61(3):375-82.
DOI:10.1212/01.wnl.0000078940.53438.83, PMID: 12913201
14. Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018;19(1):50. DOI:10.1186/s10194-018-0875-x, PMID: 30003412, PMCID: PMC6043466
15. Мербаум П.А., Табеева Г.Р., Сергеев А.В. Лекарственно-индуцированная головная боль: анализ терапевтических стратегий. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):25-31 [Merbaum PA, Tabeeva GR, Sergeev AV. Drug-induced headache: an analysis of therapeutic strategies. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2020;12(4):25-31 (in Russian)]. DOI:10.14412/2074-2711-2020-4-25-31
16. Rapoport AM. Medication overuse headache: awareness, detection and treatment. CNS Drugs. 2008;22:995-1004. DOI:10.2165/0023210-200822120-00003
17. Brusa P, Allais G, Scarinzi C, et al. Self-medication for migraine: A nationwide cross-sectional study in Italy. PLoS One. 2019;14(1):e0211191. DOI:10.1371/journal.pone.0211191, PMID: 30673780, PMCID: PMC6343913
18. Mehuys E, Paemeleire K, Van Hees T, et al. Self-medication of regular headache: a community pharmacy-based survey. Eur J Neurol. 2012;19:1093-9.
DOI:10.1111/j.1468-1331.2012.03681.x
19. Hedenrud T, Babic N, Jonsson P. Medication overuse headache: selfperceived and actual knowledge among pharmacy staff. Headache. 2014;54:1019-25. DOI:10.1111/head.12350
20. Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018;38(7):1316-25. DOI:10.1177/0333102417736898
21. Westergaard ML, Hansen EH, Glumer C, Jensen RH. Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse. Eur J Clin Pharmacol. 2015;71:851-60. DOI:10.1007/s00228-015-1858-3
22. Brusa P, Allais G, Scarinzi C, et al. Self-medication for migraine: A nationwide cross-sectional study in Italy. PLoS One. 2019;14(1):e0211191. DOI:10.1371/journal.pone.0211191, PMID: 30673780, PMCID: PMC6343913
23. Negro A, Curto M, Lionetto L, et al. A critical evaluation on MOH current treatments. Curr Treat Options Neurol. 2017;19:32. DOI:10.1007/s11940-017-0465-2
24. Westergaard ML, Glümer C, Hansen EH, Jensen RH. Medication overuse, healthy lifestyle behaviour and stress in chronic headache: results from a population-based representative survey. Cephalalgia. 2016;36:15-28. DOI:10.1177/0333102415578430
25. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097-105. DOI:10.1111/j.1468-2982.2006.01175.x
26. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13:281-90. DOI:10.1007/s10194-012-0432-y
27. Bekkelund SI, Salvesen R. Patient satisfaction with a neurological specialist consultation for headache. Scand J Prim Health Care. 2002;20:157-60. DOI:10.1080/028134302760234609
28. Lai JT, Dereix JD, Ganepola RP, et al. Should we educate about the risks of medication overuse headache? J Headache Pain. 2014;15:10. DOI:10.1186/1129-2377-15-10
29. Grande RB, Aaseth K, Benth JS, et al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011;18:129-37. DOI:10.1111/j.1468-1331.2010.03094.x
30. Fritsche G, Frettlöh J, Hüppe M, et al. Prevention of medication overuse in patients with migraine. Pain. 2010;151:404-13. DOI:10.1016/j.pain.2010.07.032
31. Kristoffersen ES, Straand J, Vetvik KG, et al. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry. 2015;86:505-12. DOI:10.1136/jnnp-2014-308548
32. Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011;18:396-401. DOI:10.1111/j.1468-1331.2010.03157.x
33. Lagman-Bartolome AM, Lawler V, Lay C. Headache education active-waiting directive: a program to enhance well-being during long referral wait times. Headache. 2018;58:109-17. DOI:10.1111/head.13194
34. Шагбазян А.Э., Ковальчук Н.А., Табеева Г.Р. Роль образовательных программ в ведении пациентов с медикаментозно-индуцированной головной болью. Неврология, нейропсихиатрия, психосоматика. 2021;13(3):27-33 [Shagbazyan AE, Kovalchuk NA, Tabeeva GR. Role of educational programs in management of patients with medicationoveruse headache. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2021;13(3):27-33 (in Russian)]. DOI:10.14412/2074-2711-2021-3-27-33
35. Diener HC, Holle D, Dresler T, Gaul C. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int. 2018;115:365-70. DOI:10.3238/arztebl.2018.0365
________________________________________________
1. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12:575-83. DOI:10.1038/nrneurol.2016.124
2. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9:391-401.
DOI:10.1016/S1474-4422(10)70008-9
3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia. 2018;38:1-211.
4. Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-25. DOI:10.1177/0333102413512033
5. Aaseth K, Grande RB, Kvaerner KJ, et al. Prevalence of secondary chronic headaches in a population-based sample of 30–44-year-old persons. The Akershus study of chronic headache. Cephalalgia. 2008;28:705-13. DOI:10.1111/j.1468-2982.2008.01577.x
6. Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012;32(5):373-81. DOI:10.1177/0333102412438977, PMID: 22395797
7. Find NL, Terlizzi R, Munksgaard SB, et al. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain. 2015;17:20. DOI:10.1186/s10194-016-0612-2, PMID: 26957090, PMCID: PMC4783306
8. Bendtsen L, Munksgaard S, Tassorelli C, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34(6):426-33. DOI:10.1177/0333102413515338, PMID: 24322480
9. Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021;61(2):351-62. DOI:10.1111/head.14056, PMID: 33432635
10. Schwedt TJ, Buse DC, Argoff CE, et al. Medication Overuse and Headache Burden Results From the CaMEO Study. Neurol Clin Pract. 2021;11(3):216-26. DOI:10.1212/CPJ.0000000000001037
11. Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25(1):12-5.
DOI:10.1111/j.1468-2982.2004.00789.x, PMID: 15606564
12. Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18(9):891-902.
DOI:10.1016/S1474-4422(19)30146-2, PMID: 31174999
13. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61(3):375-82.
DOI:10.1212/01.wnl.0000078940.53438.83, PMID: 12913201
14. Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018;19(1):50. DOI:10.1186/s10194-018-0875-x, PMID: 30003412, PMCID: PMC6043466
15. Merbaum PA, Tabeeva GR, Sergeev AV. Drug-induced headache: an analysis of therapeutic strategies. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2020;12(4):25-31 (in Russian). DOI:10.14412/2074-2711-2020-4-25-31
16. Rapoport AM. Medication overuse headache: awareness, detection and treatment. CNS Drugs. 2008;22:995-1004. DOI:10.2165/0023210-200822120-00003
17. Brusa P, Allais G, Scarinzi C, et al. Self-medication for migraine: A nationwide cross-sectional study in Italy. PLoS One. 2019;14(1):e0211191. DOI:10.1371/journal.pone.0211191, PMID: 30673780, PMCID: PMC6343913
18. Mehuys E, Paemeleire K, Van Hees T, et al. Self-medication of regular headache: a community pharmacy-based survey. Eur J Neurol. 2012;19:1093-9.
DOI:10.1111/j.1468-1331.2012.03681.x
19. Hedenrud T, Babic N, Jonsson P. Medication overuse headache: selfperceived and actual knowledge among pharmacy staff. Headache. 2014;54:1019-25. DOI:10.1111/head.12350
20. Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018;38(7):1316-25. DOI:10.1177/0333102417736898
21. Westergaard ML, Hansen EH, Glumer C, Jensen RH. Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse. Eur J Clin Pharmacol. 2015;71:851-60. DOI:10.1007/s00228-015-1858-3
22. Brusa P, Allais G, Scarinzi C, et al. Self-medication for migraine: A nationwide cross-sectional study in Italy. PLoS One. 2019;14(1):e0211191. DOI:10.1371/journal.pone.0211191, PMID: 30673780, PMCID: PMC6343913
23. Negro A, Curto M, Lionetto L, et al. A critical evaluation on MOH current treatments. Curr Treat Options Neurol. 2017;19:32. DOI:10.1007/s11940-017-0465-2
24. Westergaard ML, Glümer C, Hansen EH, Jensen RH. Medication overuse, healthy lifestyle behaviour and stress in chronic headache: results from a population-based representative survey. Cephalalgia. 2016;36:15-28. DOI:10.1177/0333102415578430
25. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097-105. DOI:10.1111/j.1468-2982.2006.01175.x
26. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13:281-90. DOI:10.1007/s10194-012-0432-y
27. Bekkelund SI, Salvesen R. Patient satisfaction with a neurological specialist consultation for headache. Scand J Prim Health Care. 2002;20:157-60. DOI:10.1080/028134302760234609
28. Lai JT, Dereix JD, Ganepola RP, et al. Should we educate about the risks of medication overuse headache? J Headache Pain. 2014;15:10. DOI:10.1186/1129-2377-15-10
29. Grande RB, Aaseth K, Benth JS, et al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011;18:129-37. DOI:10.1111/j.1468-1331.2010.03094.x
30. Fritsche G, Frettlöh J, Hüppe M, et al. Prevention of medication overuse in patients with migraine. Pain. 2010;151:404-13. DOI:10.1016/j.pain.2010.07.032
31. Kristoffersen ES, Straand J, Vetvik KG, et al. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry. 2015;86:505-12. DOI:10.1136/jnnp-2014-308548
32. Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011;18:396-401. DOI:10.1111/j.1468-1331.2010.03157.x
33. Lagman-Bartolome AM, Lawler V, Lay C. Headache education active-waiting directive: a program to enhance well-being during long referral wait times. Headache. 2018;58:109-17. DOI:10.1111/head.13194
34. Shagbazyan AE, Kovalchuk NA, Tabeeva GR. Role of educational programs in management of patients with medicationoveruse headache. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2021;13(3):27-33 (in Russian). DOI:10.14412/2074-2711-2021-3-27-33
35. Diener HC, Holle D, Dresler T, Gaul C. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int. 2018;115:365-70. DOI:10.3238/arztebl.2018.0365
Авторы
Н.А. Ковальчук*, А.Э. Шагбазян, Г.Р. Табеева
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*kowalchuk.n.a@gmail.com
________________________________________________
Nadezhda A. Koval'chuk*, Anait E. Shagbazian, Giuzial R. Tabeeva
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*kowalchuk.n.a@gmail.com